Dermasensor, a handheld AI device, can help physicians screen for skin cancer

The first health care professional to examine a skin lesion that appears suspicious to a patient is most frequently the primary care clinician. Whether the lesion is of greater concern than a normal dermatologic variation or perhaps an age-related change will be the frontline clinician's next assessment, followed by a decision to watch or to make a referral to a specialist.

In an interview with partner brand, Patient Care® dermatologist Rebecca Hartman, MD, MPH, described DermaSensor, a new FDA-approved handheld, AI-based device designed to scan and assess skin lesions in the primary care clinical setting. The device returns 1 of 2 responses following a scan: “Investigate Further,” indicating a referral, or “Monitor,” an outcome which could help rule out a majority of unnecessary referrals for benign lesions.

© Dermasensor

In the short video above, Hartman describes the device technology and highlights its sensitivity and specificity when used in primary care.